Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty
Public ClinicalTrials.gov record NCT00667446. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 36 Month, Multi-Center, Open-Label Extension Study to Evaluate the Safety of Leuprolide Acetate 11.25 mg and 30 mg Formulations in Children With Central Precocious Puberty
Study identification
- NCT ID
- NCT00667446
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Enrollment
- 72 participants
Conditions and interventions
Conditions
Interventions
- Leuprolide Acetate 3 Month Depot Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2008
- Primary completion
- Sep 30, 2012
- Completion
- Dec 31, 2012
- Last update posted
- Jan 8, 2014
2008 – 2013
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Site Reference ID/Investigator# 13521 | Birmingham | Alabama | 35233 | — |
| Site Reference ID/Investigator# 14922 | Long Beach | California | 90806 | — |
| Site Reference ID/Investigator# 26043 | Los Angeles | California | 90027 | — |
| Site Reference ID/Investigator# 20802 | San Diego | California | 92123 | — |
| Site Reference ID/Investigator# 22425 | Greenwood Village | Colorado | 80111 | — |
| Site Reference ID/Investigator# 18181 | Jacksonville | Florida | 32207 | — |
| Site Reference ID/Investigator# 26364 | Pensacola | Florida | 32504 | — |
| Site Reference ID/Investigator# 26983 | Indianapolis | Indiana | 46202 | — |
| Site Reference ID/Investigator# 20821 | Shreveport | Louisiana | 71130-3932 | — |
| Site Reference ID/Investigator# 23643 | Minneapolis | Minnesota | 55455 | — |
| Site Reference ID/Investigator# 23502 | Saint Paul | Minnesota | 55102 | — |
| Site Reference ID/Investigator# 14121 | Kansas City | Missouri | 64108 | — |
| Site Reference ID/Investigator# 23802 | Oklahoma City | Oklahoma | 73104 | — |
| Site Reference ID/Investigator# 13324 | Tulsa | Oklahoma | 74135 | — |
| Site Reference ID/Investigator# 16506 | Hershey | Pennsylvania | 17033 | — |
| Site Reference ID/Investigator# 14024 | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00667446, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2014 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00667446 live on ClinicalTrials.gov.